Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis
Background Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil. Similar observations using different chemotherapeutics may point to other drugs with a potential for repositioning. Objective This systematic r...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2022.2131298 |
| _version_ | 1797683459491102720 |
|---|---|
| author | Špela Šuler Baglama Irena Peteln Gregor B. E. Jemec |
| author_facet | Špela Šuler Baglama Irena Peteln Gregor B. E. Jemec |
| author_sort | Špela Šuler Baglama |
| collection | DOAJ |
| description | Background Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil. Similar observations using different chemotherapeutics may point to other drugs with a potential for repositioning. Objective This systematic review aims to evaluate chemotherapeutic agents linked to inflammation-induced cure of AK. Methods This systematic review was registered in PROSPERO (CRD42022346168) and followed PRISMA guidelines. A comprehensive literature search for eligible original articles written in English and published in peer-reviewed journals until July 13, 2022 was conducted in MEDLINE and Embase. Results 28 articles met inclusion criteria accounting for 36 patients (mean age 68.4 ± 8.3 years) with inflamed AK, exposed to 21 different chemotherapeutic agents – 21/36 (58.3%) received monotherapy and 15/36 (41.7%) received multidrug combinations. Regression was complete in 13/28 (46.4%) and partial in 14/28 (50.0%) of inflamed AK. Cure rates of inflamed AK in multidrug combinations were not superior to monotherapies (p = .252), leading to the observation that the majority of the former (14/15; 93.3%) encompassed one of five chemotherapeutic agents linked to AK inflammation also as a monotherapy. Conclusion Overall, inflammation partially/completely cured AK in 96.4% of patients (27/28). Taxanes, pemetrexed, and doxorubicin might have the potential for the management of AK. |
| first_indexed | 2024-03-12T00:15:46Z |
| format | Article |
| id | doaj.art-302646f9d6124971ab8f124a503b511a |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:15:46Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-302646f9d6124971ab8f124a503b511a2023-09-15T14:28:52ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-11-013383136314210.1080/09546634.2022.21312982131298Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysisŠpela Šuler Baglama0Irena Peteln1Gregor B. E. Jemec2Department of Dermatology and Venereal Diseases, University Medical Centre MariborDepartment of Dermatology and Venereal Diseases, University Medical Centre MariborDepartment of Dermatology, Zealand University HospitalBackground Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil. Similar observations using different chemotherapeutics may point to other drugs with a potential for repositioning. Objective This systematic review aims to evaluate chemotherapeutic agents linked to inflammation-induced cure of AK. Methods This systematic review was registered in PROSPERO (CRD42022346168) and followed PRISMA guidelines. A comprehensive literature search for eligible original articles written in English and published in peer-reviewed journals until July 13, 2022 was conducted in MEDLINE and Embase. Results 28 articles met inclusion criteria accounting for 36 patients (mean age 68.4 ± 8.3 years) with inflamed AK, exposed to 21 different chemotherapeutic agents – 21/36 (58.3%) received monotherapy and 15/36 (41.7%) received multidrug combinations. Regression was complete in 13/28 (46.4%) and partial in 14/28 (50.0%) of inflamed AK. Cure rates of inflamed AK in multidrug combinations were not superior to monotherapies (p = .252), leading to the observation that the majority of the former (14/15; 93.3%) encompassed one of five chemotherapeutic agents linked to AK inflammation also as a monotherapy. Conclusion Overall, inflammation partially/completely cured AK in 96.4% of patients (27/28). Taxanes, pemetrexed, and doxorubicin might have the potential for the management of AK.http://dx.doi.org/10.1080/09546634.2022.2131298chemotherapyinflammationactinic keratosestreatment |
| spellingShingle | Špela Šuler Baglama Irena Peteln Gregor B. E. Jemec Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis Journal of Dermatological Treatment chemotherapy inflammation actinic keratoses treatment |
| title | Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis |
| title_full | Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis |
| title_fullStr | Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis |
| title_full_unstemmed | Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis |
| title_short | Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis |
| title_sort | inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics a systematic review and meta analysis |
| topic | chemotherapy inflammation actinic keratoses treatment |
| url | http://dx.doi.org/10.1080/09546634.2022.2131298 |
| work_keys_str_mv | AT spelasulerbaglama inflamedactinickeratosesasabiomarkerinrepositioningofchemotherapeuticsasystematicreviewandmetaanalysis AT irenapeteln inflamedactinickeratosesasabiomarkerinrepositioningofchemotherapeuticsasystematicreviewandmetaanalysis AT gregorbejemec inflamedactinickeratosesasabiomarkerinrepositioningofchemotherapeuticsasystematicreviewandmetaanalysis |